Amygdala Neurosciences, Inc.
Palo Alto, CA Doing business as Amygdala Neurosciences Inc. Amygdala Neurosciences Inc.
- UEI
- QWM8J29664Y5
- CAGE
- 7W4G8
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 509 Hale St, Palo Alto, CA 94301, USA
- Website
- amygns.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Investigational new drug (IND)-enabling and early-stage development of selective, reversible, orally bioavailable… | National Institute on Alcohol Abuse and Alcoholism | $4,110,000 | |
| Discovery next generation inhibitors of ALDH2 to reduce craving and alcohol consumption in alcohol use disorders -… | National Institute on Alcohol Abuse and Alcoholism | $673,500 | |
| 26- & 39-week toxicity studies of ANS-6637 in rats and monkeys (respectively) to enable 6+ months dosing in alcohol (and… | National Institute on Alcohol Abuse and Alcoholism | $1,350,000 |
About Amygdala Neurosciences, Inc.
Amygdala Neurosciences, Inc., doing business as Amygdala Neurosciences Inc., is a biopharmaceutical company focused on developing and commercializing first-in-class therapies for addiction disorders. Their mission is to invent and develop medicines to treat substance use disorders. Amygdala Neurosciences is registered in SAM.gov as a for-profit corporate entity able to receive federal awards.
Amygdala Neurosciences has received several grants from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), a subsidiary of the National Institutes of Health (NIH), under the Alcohol Research Programs (CFDA 93.273). A $2 million cooperative agreement funds development of their selective, reversible aldehyde dehydrogenase 2 (ALDH2) inhibitor ANS-00858 to treat alcohol use disorder, including efficacy studies in animal models and IND-enabling activities. A $673,500 project grant supports discovery of next-generation potent, selective, reversible ALDH2 inhibitors using an innovative screening approach to reduce alcohol craving and consumption while avoiding off-target effects seen with disulfiram. Another $1.35 million cooperative agreement funded 26- and 39-week toxicity studies in rats and monkeys, respectively, for their compound ANS-6637 to enable longer-term dosing in Phase 3 trials for alcohol and substance use disorders. Amygdala's grant work aims to develop improved, safer pharmacotherapies targeting the ALDH2 enzyme for treating addictions.
Quick answers
What is Amygdala Neurosciences, Inc.'s UEI?
Amygdala Neurosciences, Inc.'s Unique Entity ID (UEI) in SAM.gov is QWM8J29664Y5.
What is Amygdala Neurosciences, Inc.'s CAGE code?
Amygdala Neurosciences, Inc.'s CAGE code is 7W4G8.
Where is Amygdala Neurosciences, Inc. located?
Amygdala Neurosciences, Inc.'s physical address in SAM.gov is 509 Hale St, Palo Alto, CA 94301, USA.
Is Amygdala Neurosciences, Inc. registered in SAM.gov?
Yes. Amygdala Neurosciences, Inc.'s SAM.gov registration is active through August 15, 2027.
What is Amygdala Neurosciences, Inc.'s most recent federal award?
Amygdala Neurosciences, Inc.'s most recent federal grant award is Investigational new drug (IND)-enabling and early-stage development of selective, reversible, orally bioavailable… (U43AA030689), from National Institute on Alcohol Abuse and Alcoholism, on August 1, 2023.
On GovTribe
See Amygdala Neurosciences, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors